Table 2.
≤5 ng/L | 6–8 ng/L | 9–13 ng/L | ≥14 ng/L | P for trend | P for interaction* | |
---|---|---|---|---|---|---|
Overall | ||||||
Model 1 | Reference | 1.09 (0.97–1.23) | 1.35 (1.16–1.56) | 1.66 (1.36–2.02) | <0.001 | – |
Model 2 | Reference | 0.98 (0.86–1.11) | 1.14 (0.99–1.33) | 1.25 (1.03–1.53) | 0.018 | – |
Model 3 | Reference | 0.93 (0.82–1.05) | 1.12 (0.96–1.30) | 1.13 (0.93–1.38) | 0.154 | – |
Undiagnosed diabetes | ||||||
Model 1 | Reference | 0.95 (0.72–1.24) | 1.03 (0.74–1.43) | 0.86 (0.59–1.24) | 0.538 | – |
Model 2 | Reference | 0.94 (0.71–1.25) | 1.13 (0.79–1.62) | 0.84 (0.57–1.23) | 0.615 | – |
Model 3 | Reference | 0.87 (0.66–1.16) | 1.09 (0.77–1.55) | 0.81 (0.55–1.19) | 0.485 | – |
Fasting glucose | ||||||
Normal | ||||||
Model 1 | Reference | 0.95 (0.73–1.23) | 1.07 (0.75–1.51) | 2.13 (1.44–3.15) | 0.014 | <0.001 |
Model 2 | Reference | 0.91 (0.70–1.19) | 1.02 (0.72–1.44) | 1.81 (1.22–2.70) | 0.078 | <0.001 |
Model 3 | Reference | 0.91 (0.70–1.19) | 1.02 (0.72–1.45) | 1.82 (1.22–2.71) | 0.072 | 0.012 |
Impaired | ||||||
Model 1 | Reference | 1.03 (0.88–1.21) | 1.33 (1.10–1.61) | 1.21 (0.90–1.62) | 0.009 | – |
Model 2 | Reference | 0.93 (0.79–1.10) | 1.15 (0.95–1.39) | 0.96 (0.71–1.29) | 0.578 | – |
Model 3 | Reference | 0.94 (0.79–1.10) | 1.12 (0.93–1.36) | 0.96 (0.72–1.29) | 0.661 | – |
Metabolic syndrome | ||||||
No | ||||||
Model 1 | Reference | 0.97 (0.79–1.20) | 1.07 (0.82–1.40) | 1.70 (1.23–2.37) | 0.027 | <0.001 |
Model 2 | Reference | 0.91 (0.74–1.12) | 1.00 (0.76–1.31) | 1.54 (1.10–2.15) | 0.150 | <0.001 |
Model 3 | Reference | 0.80 (0.65–1.00) | 0.95 (0.72–1.25) | 1.47 (1.05–2.05) | 0.408 | <0.001 |
Yes | ||||||
Model 1 | Reference | 1.08 (0.93–1.26) | 1.34 (1.12–1.60) | 1.39 (1.09–1.77) | <0.001 | – |
Model 2 | Reference | 1.01 (0.87–1.18) | 1.21 (1.01–1.45) | 1.18 (0.92–1.51) | 0.043 | – |
Model 3 | Reference | 0.96 (0.82–1.12) | 1.18 (0.98–1.41) | 1.03 (0.80–1.32) | 0.280 | – |
Model 1: age, race-center, sex; model 2: model 1 plus total cholesterol, LDL-C, HDL-C, triglycerides, cholesterol-lowering medication use, BMI, systolic blood pressure, blood pressure–lowering medication use, smoking status, eGFR, family history of coronary heart disease, waist circumference, physical activity, education level, and annual family income level; model 3: model 2 plus fasting glucose.
*P value for interaction within the respective subgroup, where applicable.